Virologica Sinica

, Volume 23, Issue 6, pp 486–495

Prevention and treatment of KSHV-associated diseases with antiviral drugs

Authors

  • Ren-rong Tian
    • State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of Sciences
  • Qing-jiao Liao
    • State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of Sciences
    • State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of Sciences
Article

DOI: 10.1007/s12250-008-2995-y

Cite this article as:
Tian, R., Liao, Q. & Chen, X. Virol. Sin. (2008) 23: 486. doi:10.1007/s12250-008-2995-y

Abstract

Kaposi’s sarcoma-associated herpesvirus (KSHV) was first identified as the etiologic agent of Kaposi’s sarcoma (KS) in 1994. KSHV infection is necessary, but not sufficient for the development of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD). Advances in the prevention and treatment of KSHV-associated Diseases have been achieved, even though current treatment options are ineffective, or toxic to many affected persons. The identification of new targets for potential future therapies and the randomized trial to evaluate the efficacy of new antivirals are required.

Key words

Antiviral drugsKaposi’s sarcoma-associated herpesvirus (KSHV)Kaposi’s sarcoma (KS)Primary effusion lymphomaMulticentric castleman disease

CLC number

Q786
Download to read the full article text

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag GmbH 2008